Furthermore, beyond the immediate trial, there is a broader potential for approval and product launches from Rocket’s lentiviral vector-based therapies, which adds to the investment case. The Phase 2 ...

The darkest-darkest timeline is the one where the world’s richest man runs a communications platform in a truly vengeful, ...

Fintel reports that on September 12, 2024, JMP Securities initiated coverage of Rocket Lab USA (NasdaqCM:RKLB) with a Market ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

In the latest round of blasts, exploding walkie-talkies killed 14 and injured at least 450 people, according to Lebanon's ...

Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the ...

Ukraine will likely receive a number of AGM-154 Joint Standoff Weapon (JSOW) glide munitions in a new $375 million U.S. aid ...

Happy butterscotch pudding day from the wBW team! We’ve put together the freshest news from our good industry.

The company said the single-arm multicenter Phase II trial may support accelerated approval for the RP-A501 gene therapy in the US.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

Australia and India are expanding their space collaboration, focusing on supporting India's Gaganyaan mission and launching ...

The panel will share insights at TechCrunch Disrupt 2024 on the data evolution and the strategies companies need to use to stay ahead in a data-driven world.